5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

3. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Biotechnology Value Fund’s Stake Value: $168,484,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 6.31%
Number of Hedge Fund Holders: 27

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) presented a positive hedge fund sentiment in Q2, as 27 hedge funds in Insider Monkey database were bullish on the company, compared with 20 in the previous quarter. The total value of these stakes is $723.5 million. Consonance Capital Management is one of the largest shareholders of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in Q2, with shares worth $154.6 million. The company stands third on our list of the best biotech stocks to buy according to Mark Lampert.

In Q2, BVF holds over 3.7 million shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at $168.4 million. The company accounts for 6.31% of the hedge fund’s 13F portfolio.